“Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s729. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/4040.